-
-
-
-
-
-
-
Allurion reports 23% weight loss combining balloon therapy with tirzepatide
-
-
-
-
-
-
-
Allurion reports 95% weight maintenance one year after balloon treatment
-
-
-
-
-
-
-
Allurion Technologies (ALUR) Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence
-
-
-
-
-
-
-
Allurion Technologies (ALUR) Announces $2.5M Share Placement, Reports Prelim Q4 Results
-
-
-
-
-
-
-
Allurion Technologies (ALUR) Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss
-
-
-
-
-
-
-
Allurion Technologies (ALUR) Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program
-
-
-
-
-
416,816 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

